Scarica l'app Stockscreener
71.05
0.69%
0.49
Pre-mercato:
71.93
0.88
+1.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$70.56
Aprire:
$70.66
Volume 24 ore:
2.14M
Relative Volume:
1.08
Capitalizzazione di mercato:
$13.69B
Reddito:
$4.08B
Utile/perdita netta:
$32.48M
Rapporto P/E:
37.59
EPS:
1.89
Flusso di cassa netto:
$16.80M
1 W Prestazione:
-11.72%
1M Prestazione:
+7.02%
6M Prestazione:
+24.24%
1 anno Prestazione:
+29.87%
Intervallo 1D:
$70.25
$71.68
Intervallo di 1 settimana:
$65.02
$80.46
Portata 52W:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| INCY | 71.05 | 13.69B | 4.08B | 32.48M | 16.80M | 1.89 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
What Are Wall Street Analysts' Target Price For Incyte Stock? - Barchart
What Are Wall Street Analysts' Target Price for Incyte Stock? - Inkl
Merck (MRK) Eyes Incyte (INCY) for Possible Acquisition - Value the Markets
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
U.S. Indexes Ended Tuesday Mixed As Super Micro Computer Led, Incyte Lagged - Barron's
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - AOL
Incyte stock maintains Outperform rating despite study pause - Investing.com
Incyte (NASDAQ:INCY) Shares Gap DownHere's Why - MarketBeat
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Yahoo Finance
Merck ‘linked’ to takeover bid for Incyte, Sky News says - TipRanks
Incyte seesaws on report of potential Merck takeover interest (NASDAQ:INCY) - Seeking Alpha
What's Going On With Incyte Shares Tuesday? - Benzinga
Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. - MSN
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Investopedia
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Incyte Stock Is S&P 500’s Worst Performer. Here’s Why. - Barron's
Incyte Faces Challenges but Remains Focused on Strategic Growth - Yahoo Finance
Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. - Yahoo! Voices
Incyte (NASDAQ:INCY) Given Neutral Rating at Cantor Fitzgerald - MarketBeat
Incyte price target lowered to $86 from $90 at BofA - TipRanks
RBC maintains sector perform on Incyte shares, cuts target following '262 pause - Investing.com
One Paused, One Dropped: Incyte’s Skin Drug Acquisitions Hit Problems - Citeline News & Insights
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace
Incyte culls one Escient-acquired dermatology programme, pauses another - FirstWord Pharma
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more - Investing.com
Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - TipRanks
Incyte (INCY) will pause enrollment in ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria - StreetInsider.com
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs - Yahoo Finance
Dr. Pimple Popper gets personal with eczema in Incyte’s Moments of Clarity push - MM+M Online
Seizert Capital Partners LLC Has $6.24 Million Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects - Insider Monkey
Incyte Co. (NASDAQ:INCY) Shares Purchased by Mizuho Securities USA LLC - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Principal Financial Group Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte price target raised to $80 from $72 at RBC Capital - TipRanks
KBC Group NV Sells 563,357 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses By Investing.com - Investing.com Australia
Incyte to Present at Citi's 2024 Global Healthcare Conference in Miami | INCY Stock News - StockTitan
INCY (Incyte) Cash Flow from Operations : $102 Mil (TTM As of Sep. 2024) - GuruFocus.com
Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses - Investing.com
Anal Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - The Globe and Mail
Anal Cancer Market Revenue to Expand Significantly by 2034, - openPR
Incyte Co. (NASDAQ:INCY) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Amalgamated Bank - MarketBeat
Los Angeles Capital Management LLC Lowers Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.90%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):